Home › Free Stock Grades › NBIX
Neurocrine Biosciences, Inc. (NBIX) Stock Grade
NBIX · Healthcare
A+
Market Cap
$15.4B
P/E Ratio
29.5
Revenue Growth (YoY)
+21.5%
Net Margin
16.7%
Return on Equity
14.7%
Dividend Yield
None
About Neurocrine Biosciences, Inc.'s fundamentals
Neurocrine Biosciences is a $15.4 billion biotech company demonstrating solid operational performance with 21.5% year-over-year revenue growth and a net profit margin of 16.7%, indicating efficient conversion of sales to profits. The company generates a 14.7% return on equity, showing reasonable returns on shareholder capital, though its 29.5 P/E ratio suggests investors are pricing in future growth expectations. The company does not currently pay a dividend, typical for biotech firms that often reinvest earnings into research and development.